


Reference Data

(Consolidated Financial Results for Q2 FY2014)



Daiichi-Sankyo

October 31, 2014

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Summary of Consolidated Statement of Profit or Loss	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Revenue by Business Units	P3
5.	Revenue of Global Products	P4
6.	Number of Employees	P5
7.	Management / Financial Indicators	P6
8.	Capital Expenditure and Depreciation and Amortization	P6
9.	Consolidated Statement of Financial Position	P7
10.	Consolidated Statement of Cash Flows	P9
11.	Accounting Treatment when Ranbaxy group is Unconsolidated	P10
12.	Summary of Product Outlines	P11

Supplemental Information

Historical Data

1. Summary of Consolidated Statement of Profit or Loss

JPY Bn	Q1			Q2			Q3			Q4			Q2 YTD				FY2014		
	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	YoY	to revenue	Forecast	from Jul
Revenue	100%	254.4	+0.7%	100%	271.0	+2.6%							100%	525.4	8.6	+1.7%	100%	900.0	-20.0
Cost of sales	34%	85.9	-2.0%	33%	90.2	+4.4%							34%	176.1	2.1	+1.2%	31.1%	280.0	-5.0
Gross Profit	66%	168.6	+2.1%	67%	180.7	+1.7%							66%	349.3	6.6	+1.9%	68.9%	620.0	-15.0
SG&A expenses	38%	96.0	-5.7%	35%	95.7	+2.4%							36%	191.6	-3.5	-1.8%	37.6%	338.0	5.0
(General expenses) ^{*1}	36%	92.7	+5.3%	34%	92.1	+1.6%							35%	184.8	6.1	+3.4%			
(Asset related expenses) ^{*2}	1%	3.3	+13.7%	1%	3.6	+28.5%							1%	6.9	1.2	+21.0%			
(Loss on restructuring)		-		0%	-0.0	-55.4%							0%	-0.0	-10.8	-100.2%			
R&D expenses	17%	43.2	-10.3%	17%	45.6	-2.3%							17%	88.8	-6.0	-6.3%	20.2%	182.0	0.0
Operating Profit	12%	29.4	+93.9%	15%	39.4	+5.0%							13%	68.8	16.1	+30.6%	11.1%	100.0	-20.0
Financial income/expenses		-1.1			-1.4									-2.5	6.0				
Share of profit or loss of investments accounted for using the equity method		-0.4			-0.6									-1.0	-0.6				
Profit before tax	11%	27.9	+59.4%	14%	37.4	+42.1%							12%	65.4	21.5	+49.0%	11.1%	100.0	-20.0
Income taxes		9.4			5.7									15.1	2.8				
Profit for the year	7%	18.5			31.8									50.3	18.7				
Profit attributable to owners of the Company	8%	20.0	+33.0%	11%	30.3	+64.4%							10%	50.3	16.8	+50.3%	7.2%	65.0	-13.0
Effective tax rate		34%			15%									23%					
Overseas sales ratio results		54%			53%									53%					

Notes to FY2014 Q2 YTD Results Year-on-Year Comparisons

Revenue	Japan company, others -4.9 (Nexium +8.1, Memyary +2.4, Pralia +2.0, Teneria +3.1, Loxonin -5.3, Mevalotin -2.8, Vaccines -5.0, Cravit -1.5) Daiichi Sankyo Inc. -8.4 (Olmesartan -9.6), Luitpold +8.5 (Venofer +2.5, Injectafer +2.7), Daiichi Sankyo Europe +4.1 (Olmesartan +4.2), ASCA company +3.1, Ranbaxy +8.0 Currency impact (appreciation of JPY to USD and EUR +7.4, appreciation of JPY to INR -1.1)
SG&A expenses	: -3.5 Currency impact (depreciation of JPY to USD, EUR, and INR +3.0), Gains from sales of fixed assets +2.2, Loss on restructuring in Daiichi Sankyo Europe GmbH in FY2013 1Q -10.8 ^{*1} Incl. A&P expenses, Personnel expenses and other SG&A expenses ^{*2} Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.
R&D expenses	: -6.0 Currency impact (depreciation of JPY to USD, EUR, and INR +1.6)
Financial income/expenses	: +6.0 Foreign exchange gain etc.
Income taxes	: +2.8 Increase of Profit before tax, a tax effect caused by impairment of Ranbaxy's asstes in past fiscal years was recognized in FY2014 Q2 Dividend received from U3 Pharma was considered as devaluation of book value resulted in tax benefit in FY2013

2. Currency Rate

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	Q2 YTD	FY2014
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	102.16	103.05			103.05	+4.19
EUR/JPY (average)	140.06	138.91			138.91	+8.90
INR/JPY (average)	1.72	1.72			1.72	-0.02

Depreciation in JPY against USD, EUR, and INR positively affected the FY2014 Q2 YTD results by 6.3 bil yen in revenue and 2.2 bil yen in operating profit.
Annual impact of one yen change is estimated to affect the group's FY2014 performance by; USD: revenue 2.2 bil yen, operating profit minor / EUR: revenue 0.6 bil yen, operating profit minor

Forecast for Q3 and Q4
USD/JPY:105, EUR/JPY:140

*Please see page 10 for Accounting Treatment when Ranbaxy Group is Unconsolidated (Planned)
*Please see page 1-2 of Historical Data for the IFRS based result of FY2013 (quarterly)

3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q2 YTD				FY2014		
	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	YoY	to revenue	Forecast	from Jul
External revenue		213.4	+1.6%		215.6	-1.2%								429.0	0.6	+0.1%			
Intersegment revenue		0.3			0.3									0.6	-0.2				
Revenue	100%	213.7	+1.6%	100%	215.9	-1.3%							100%	429.6	0.5	+0.1%	100%	900.0	-20.0
Cost of sales	30%	64.6	-2.0%	31%	66.2	+4.5%							30%	130.8	1.5	+1.2%	31.1%	280.0	-5.0
Gross Profit	70%	149.1	+3.2%	69%	149.7	-3.7%							70%	298.8	-1.1	-0.4%	68.9%	620.0	-15.0
SG&A expenses	35%	75.6	-10.1%	37%	79.6	+5.2%							36%	155.2	-4.5	-2.8%	37.6%	338.0	5.0
(General expenses)* ¹	34%	73.4	+1.9%	36%	77.0	+3.5%							35%	150.5	4.0	+2.7%			
(Asset related expenses)* ²	1%	2.1	+77.3%	1%	2.6	+110.6%							1%	4.7	2.3	+94.1%			
(Loss on restructuring)				0%	-0.0	-52.8%							0%	-0.0	-10.8	-100.2%			
R&D expenses	19%	41.4	-9.6%	20%	43.5	-1.7%							20%	84.9	-5.2	-5.7%	20.2%	182.0	0.0
Operating Profit	15%	32.1	+120.2%	12%	26.6	-25.1%							14%	58.7	8.6	+17.2%	11.1%	100.0	-20.0
Financial income and expense		0.2			2.5									2.8	2.5				
Share of profit or loss of investments accounted for using the equity method		-0.3			-0.5									-0.8	-0.7				
Profit before tax	15%	32.0	+100.9%	13%	28.6	-16.4%							14%	60.7	10.5	+20.8%	11.1%	100.0	-20.0
Income taxes		11.6			15.0									26.6	10.7				
Profit for the year		20.5			13.6									34.1	-0.3				
Profit attributable to owners of the Company	10%	21.1	+51.9%	7%	14.3	-32.6%							8%	35.5	0.3	+0.8%	7.2%	65.0	-13.0
Ranbaxy Group	Q1			Q2			Q3			Q4			Q2 YTD				FY2014		
	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	YoY	to revenue	Forecast	from Jul
External revenue		41.1	-3.6%		55.3	+20.9%								96.4	8.0	+9.1%			
Intersegment revenue		0.5			0.4									0.9	0.3				
Revenue	100%	41.6	-3.1%	100%	55.8	+20.9%							100%	97.4	8.3	+9.3%			
Cost of sales	53%	22.0	-1.2%	44%	24.8	+4.4%							48%	46.8	0.8	+1.7%			
Gross Profit	47%	19.6	-5.2%	56%	31.0	+38.6%							52%	50.5	7.6	+17.6%			
SG&A expenses	47%	19.6	+15.8%	27%	15.3	-20.1%							36%	34.8	-1.2	-3.3%			
R&D expenses	5%	1.9	-25.3%	4%	2.3	-13.2%							4%	4.2	-1.0	-19.2%			
Operating Profit	-5%	-1.9	-263.2%	24%	13.4	+2149.5%							12%	11.5	9.7	+551.6%			
Financial income and expense		-1.4			-4.0									-5.5	3.4				
Share of profit or loss of investments accounted for using the equity method		-0.0			-0.0									-0.1	0.1				
Profit before tax	-8%	-3.4	-259.6%	17%	9.4	-199.7%							6%	6.0	13.2	-182.2%			
Income taxes		-1.9			3.0									1.0	4.7				
Profit for the year		-1.5			6.4									4.9	8.5				
Profit attributable to owners of the Company	-3%	-1.4	-155.1%	11%	6.4	-202.4%							5%	5.0	8.7	-235.1%			
Inter-segment Transactions	Q1			Q2			Q3			Q4			Q2 YTD				FY2014		
	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	to revenue	Results	YoY	YoY	to revenue	Forecast	from Jul
Revenue		-0.8			-0.7									-1.6	-0.1				
Cost of sales		-0.7			-0.8									-1.5	-0.2				
Gross Profit		-0.1			0.1									-0.0	0.1				
SG&A expenses		0.8			0.8									1.7	2.2				
R&D expenses		-0.1			-0.1									-0.3	0.1				
Operating Profit		-0.8			-0.6									-1.4	-2.2				
Financial income and expense		0.1			0.1									0.2	0.1				
Share of profit or loss of investments accounted for using the equity method		-0.0			-0.0									-0.1	0.0				
Profit before tax		-0.7			-0.5									-1.3	-2.2				
Income taxes		-0.3			-12.3									-12.6	-12.6				
Profit for the year		-0.5			11.8									11.3	10.4				
Profit attributable to owners of the Company		0.2			9.6									9.8	7.9				

*¹ Incl. A&P expenses, Personnel expenses and other SG&A expenses

*² Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

4. Revenue by Business Units

	FY2014			Q1			Q2			Q3			Q4			Q2 YTD			
	Plan(Jul)	Plan(Oct)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																			
Japan Company (domestic sales)+Vaccine business	508.0	480.0	-28.0	108.0	-1.3%	23%	114.6	-3.0%	24%							222.6	-4.9	-2.2%	46%
Olmotec	79.0	79.0	0.0	18.7	+12.7%	24%	19.1	-8.8%	24%							37.8	0.3	+0.7%	48%
Nexium	67.0	67.0	0.0	15.3	+39.4%	23%	16.8	+28.8%	25%							32.1	8.1	+33.7%	48%
Loxonin	52.0	48.0	-4.0	12.2	-18.0%	26%	13.2	-16.4%	27%							25.4	-5.3	-17.2%	53%
Mema	50.0	39.0	-11.0	7.9	+19.0%	20%	8.9	+14.3%	23%							16.8	2.4	+16.4%	43%
Cravit	29.0	27.0	-2.0	6.9	-9.9%	26%	7.3	-9.7%	27%							14.2	-1.5	-9.8%	53%
Rezaltas	22.0	18.0	-4.0	4.5	+4.2%	25%	4.5	-3.3%	25%							9.0	0.0	+0.3%	50%
Artist	21.0	18.0	-3.0	4.8	-11.7%	27%	4.7	-17.7%	26%							9.4	-1.6	-14.8%	52%
Mevalotin	17.0	16.0	-1.0	4.2	-19.9%	26%	4.1	-29.9%	26%							8.3	-2.8	-25.2%	52%
Omnipaque	15.0	17.0	2.0	4.2	-10.5%	25%	4.4	-16.4%	26%							8.6	-1.4	-13.6%	51%
Pralia	12.0	7.0	-5.0	1.3	+250.9%	18%	1.7	+200.8%	25%							3.0	2.0	+220.1%	43%
Ranmark	10.0	10.0	0.0	2.1	+34.0%	21%	2.6	+36.8%	26%							4.7	1.2	+35.5%	47%
Inavir	10.0	13.0	3.0	0.3	+7.9%	2%	0.0	+38.7%	0%							0.3	0.0	+8.6%	2%
Urief	10.0	10.0	0.0	2.7	+2.5%	27%	2.9	-1.5%	29%							5.6	0.0	+0.4%	56%
Teneria	not disclosed	not disclosed		1.5	N.M	-	1.8	N.M	-							3.3	3.1	+2265.2%	-
Lixiana	not disclosed	not disclosed		0.1	+2.5%	-	0.1	+7.5%	-							0.2	0.0	+4.9%	-
Effient	not disclosed	not disclosed		0.2	-	-	0.1	-	-							0.3	0.3	-	-
Daiichi Sankyo Espha products	not disclosed	not disclosed		3.5	+18.4%	-	3.3	+10.1%	-							6.8	0.8	+14.2%	-
Vaccines business	not disclosed	not disclosed		5.8	-37.5%	-	6.7	-18.5%	-							12.5	-5.0	-28.5%	-
Daiichi Sankyo Healthcare (OTC)	48.0	48.0	0.0	9.4	-4.0%	20%	13.3	+1.3%	28%							22.7	-0.3	-1.4%	47%
Daiichi Sankyo, Inc. (US)	164.0	161.0	-3.0	41.6	-10.8%	26%	36.5	-8.4%	23%							78.1	-8.4	-9.7%	49%
Olmesartan	105.0	98.0	-7.0	25.7	-16.4%	26%	21.5	-17.4%	22%							47.2	-9.6	-16.8%	48%
Benicar/Benicar HCT	77.0	71.0	-6.0	18.9	-20.6%	27%	15.1	-25.1%	21%							34.0	-10.0	-22.7%	48%
Azor	17.0	17.0	0.0	4.1	-10.6%	24%	3.9	+3.5%	23%							8.0	-0.4	-4.3%	47%
Tribenzor	9.0	10.0	1.0	2.7	+15.6%	27%	2.5	+19.6%	25%							5.2	0.8	+17.5%	52%
Welchol	41.0	44.0	3.0	11.3	-0.7%	26%	10.5	+8.7%	24%							21.8	0.8	+3.7%	50%
Effient (alliance revenue)	not disclosed	not disclosed		4.2	+6.1%	-	4.2	+16.6%	-							8.5	0.8	+11.0%	-
Luitpold Pharmaceuticals, Inc. (US)	50.0	53.0	3.0	12.5	+54.3%	24%	14.3	+40.3%	27%							26.8	8.5	+46.5%	51%
Venofer	19.0	26.0	7.0	7.2	+45.6%	28%	7.0	+3.8%	27%							14.2	2.5	+21.5%	55%
Injectafer	10.0	7.0	-3.0	1.5	-	21%	1.5	+508.2%	21%							2.9	2.7	+1108.0%	42%
Daiichi Sankyo Europe GmbH	81.0	84.0	3.0	24.5	+29.0%	29%	20.0	-6.5%	24%							44.5	4.1	+10.2%	53%
Olmesartan	63.0	66.0	3.0	19.7	+37.5%	30%	15.7	-6.8%	24%							35.4	4.2	+13.6%	54%
Olmotec/Olmotec Plus	36.0	38.0	2.0	11.1	+13.2%	29%	9.3	-19.5%	25%							20.4	-1.0	-4.6%	54%
Sevikar	16.0	17.0	1.0	5.3	+77.8%	32%	4.2	+37.7%	25%							9.6	3.5	+57.6%	56%
Sevikar HCT	9.0	10.0	1.0	3.3	+111.1%	33%	2.1	-1.1%	21%							5.4	1.7	+46.8%	54%
Efient (alliance revenue)	not disclosed	not disclosed		1.2	+0.3%	-	1.2	+5.4%	-							2.3	0.1	+2.8%	-
Asia, South and Central America (ASCA)	59.0	64.0	5.0	15.1	+18.6%	24%	14.8	+5.0%	23%							30.0	3.1	+11.5%	47%
Daiichi Sankyo China	not disclosed	not disclosed		5.4	+14.3%	-	6.1	+24.6%	-							11.5	1.9	+19.5%	-
Daiichi Sankyo Taiwan	not disclosed	not disclosed		1.2	+9.6%	-	1.1	+4.7%	-							2.3	0.2	+7.2%	-
Daiichi Sankyo Korea	not disclosed	not disclosed		2.7	+51.3%	-	1.7	-23.9%	-							4.4	0.4	+10.2%	-
Daiichi Sankyo (Thailand)	not disclosed	not disclosed		0.7	+89.2%	-	0.9	+108.0%	-							1.6	0.8	+99.1%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	not disclosed		2.3	+34.2%	-	2.0	-1.5%	-							4.3	0.6	+14.8%	-
Daiichi Sankyo Venezuela	not disclosed	not disclosed		1.2	-0.9%	-	1.8	+0.6%	-							3.0	0.0	+0.0%	-
Ranbaxy Group	not disclosed	not disclosed		41.1	-2.9%	-	55.3	+21.2%	-							96.4	8.0	+9.1%	-

[Reference] Revenue in Local Currency

	FY2014			Q1			Q2			Q3			Q4			Q2 YTD			
	Plan(Jul)	Plan(Oct)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																			
Daiichi Sankyo, Inc. (US)	1,640	1,548	-92	407	-13.7%	26%	351	-12.9%	23%							758	-117	-13.4%	49%
Olmesartan	1,050	942	-108	251	-19.2%	27%	207	-21.4%	22%							458	-116	-20.2%	49%
Benicar/Benicar HCT	770	683	-87	185	-23.3%	27%	145	-28.9%	21%							330	-115	-25.8%	48%
Azor	170	163	-7	40	-13.6%	25%	38	-1.5%	23%							78	-7	-8.1%	48%
Tribenzor	90	96	6	26	+11.7%	27%	24	+13.8%	25%							50	6	+12.7%	52%
Welchol	410	423	13	111	-4.0%	26%	101	+3.5%	24%							211	-1	-0.6%	50%
Effient (alliance revenue)	not disclosed	not disclosed		42	+2.5%	-	41	+11.0%	-							82	5	+6.5%	-
USD Mn																			
Luitpold Pharmaceuticals, Inc. (US)	500	510	10	122	+49.1%	24%	137	+33.7%	27%							260	75	+40.6%	51%
Venofer	190	250	60	70	+40.8%	28%	68	-1.2%	27%							138	20	+16.5%	55%
Injectafer	100	67	-33	14	-	21%	14	+478.5%	21%							28	26	+1058.9%	42%
EUR Mn																			
Daiichi Sankyo Europe GmbH	579	602	23	175	+18.8%	29%	146	-11.0%	24%							321	10	+3.1%	53%
Olmesartan	450	473	23	141	+26.6%	30%	114	-11.2%	24%							255	15	+6.4%	54%
Olmetec/Olmetec Plus	257	272	15	79	+4.2%	29%	68	-23.4%	25%							147	-18	-10.7%	54%
Sevikar	114	122	8	38	+63.7%	31%	31	+31.3%	25%							69	22	+47.5%	57%
Sevikar HCT	64	72	8	24	+94.3%	33%	15	-5.7%	21%							39	11	+37.4%	55%
Efient (alliance revenue)	not disclosed	not disclosed		8	-7.7%	-	8	+0.3%	-							17	-1	-3.8%	-
INR Bn																			
Ranbaxy Group	not disclosed	not disclosed		24	-3.4%	-	33	+27.1%	-							57	6	+12.2%	-

5. Revenue of Global Products

	FY2014			Q1			Q2			Q3			Q4			Q2 YTD			
	Plan(Jul)	Plan(Oct)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																			
Olmesartan	289.0	284.0	-5.0	75.8	+3.6%	27%	66.5	-10.7%	23%							142.2	-5.3	-3.6%	50%
Olmetec (JPN)	79.0	79.0	0.0	18.7	+12.7%	24%	19.1	-8.8%	24%							37.8	0.3	+0.7%	48%
Rezaltas (JPN)	22.0	18.0	-4.0	4.5	+4.2%	25%	4.5	-3.3%	25%							9.0	0.0	+0.3%	50%
Benicar/Benicar HCT (US)	77.0	71.0	-6.0	18.9	-20.6%	27%	15.1	-25.1%	21%							34.0	-10.0	-22.7%	48%
Azor (US)	17.0	17.0	0.0	4.1	-10.6%	24%	3.9	+3.5%	23%							8.0	-0.4	-4.3%	47%
Tribenzor (US)	9.0	10.0	1.0	2.7	+15.6%	27%	2.5	+19.6%	25%							5.2	0.8	+17.5%	52%
Olmetec/Olmetec Plus (EU)	36.0	38.0	2.0	11.1	+13.2%	29%	9.3	-19.5%	25%							20.4	-1.0	-4.6%	54%
Sevikar (EU)	16.0	17.0	1.0	5.3	+77.8%	32%	4.2	+37.7%	25%							9.6	3.5	+57.6%	56%
Sevikar HCT (EU)	9.0	10.0	1.0	3.3	+111.1%	33%	2.1	-1.1%	21%							5.4	1.7	+46.8%	54%
Other subsidiaries, export, etc	24.0	24.0	0.0	7.1	-0.3%	30%	5.8	-3.5%	24%							12.9	-0.2	-1.7%	54%
Prasugrel	not disclosed	not disclosed		5.8	-0.5%	-	5.9	+17.2%	-							11.7	0.8	+7.7%	-
Effient alliance revenue (US)	not disclosed	not disclosed		4.2	+6.1%	-	4.2	+16.6%	-							8.5	0.8	+11.0%	-
Efient alliance revenue (EU)	not disclosed	not disclosed		1.2	+0.3%	-	1.2	+5.4%	-							2.3	0.1	+2.8%	-
Effient (JPN)	not disclosed	not disclosed		0.2	-	-	0.1	-	-							0.3	0.3	-	-
Other subsidiaries, export, etc	not disclosed	not disclosed		0.2	-60.6%	-	0.4	+12.3%	-							0.6	-0.3	-30.6%	-

6. Number of Employees

	Mar 2014 Results	Jun 2013 Results	Sep 2013 Results	Dec 2013 Results	Mar 2014 Results
Total Number of Employees	32,791	32,725	32,617		
Japan	9,145	9,290	9,201		
Overseas	23,646	23,435	23,416		
Daiichi Sankyo Group	17,256	17,362	17,298		
Ranbaxy Group	15,535	15,363	15,319		

7. Management / Financial Indicators

	FY2013 Results	FY2014 Q2 YTD Results	FY2014 Forecast
Management Indicators			
Basic earnings per share	86.6 Yen	71.5 Yen	92.3 Yen
Dividend per share	60.0 Yen	30.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	69.3 %	42.0 %	65.0 %
Return on equity attributable to owners of the Company	6.5 %	5.0 %	
Ratio of dividends to equity attributable to owners of the Company	4.5 %	2.1 %	
Equity per share attributable to owners of the Company	1,392.0 Yen	1,467.0 Yen	
Ratio of equity attributable to owners of the Company to total assets	52.9 %	56.2 %	
Total number of common shares	704 million	704 million	
Share price at end of period	1,738 Yen	1,721 Yen	
Market value	1,223.5 JPY Bn	1,211.6 JPY Bn	
Financial Indicators			
Total assets	1,854.0 JPY Bn	1,838.1 JPY Bn	
Current assets	990.6 JPY Bn	931.6 JPY Bn	
*1 Liquidity on hand	507.3 JPY Bn	439.0 JPY Bn	
Debt with interest	426.8 JPY Bn	362.1 JPY Bn	
Net Cash	80.5 JPY Bn	76.9 JPY Bn	
Equity capital	979.9 JPY Bn	1,032.7 JPY Bn	
Cash flows from operating activities	37.3 JPY Bn	56.8 JPY Bn	
Cash flows from investing activities	-161.4 JPY Bn	25.8 JPY Bn	
Cash flows from financial activities	100.3 JPY Bn	-92.0 JPY Bn	
*2 Free cash flows	-124.1 JPY Bn	82.6 JPY Bn	
Cash and cash equivalents at the end of the year	183.1 JPY Bn	180.3 JPY Bn	
Others			
Number of consolidated subsidiaries	96	98	

*1 Current deposits + marketable securities + investment securities, etc

*2 Cash flows from operating activities and investing activities

8. Capital Expenditure and Depreciation and Amortization

	FY2013 Results	FY2014 Q2 YTD Results	FY2014 Plan*
Capital expenditure	49.2 JPY Bn	17.7 JPY Bn	38.0 JPY Bn
Depreciation and amortization	51.5 JPY Bn	25.6 JPY Bn	39.0 JPY Bn
Property, plant and equipment	30.5 JPY Bn	16.1 JPY Bn	
Intangible assets	21.0 JPY Bn	9.5 JPY Bn	

9. Consolidated Statement of Financial Position

(Billions of yen)

	Mar 2014	Sep 2014	YoY	Notes
Assets				
Current assets				
Cash and cash equivalents	183.1	180.3	-2.8	
Trade and other receivables	269.2	271.1	1.9	
Other financial assets	324.2	260.7	-63.5	Daiichi Sankyo -80.9 Bn
Inventories	189.4	204.5	15.1	
Other current assets	24.8	15.1	-9.7	
Total current assets	990.6	931.6	-59.0	
Non-current assets				
Property, plant and equipment	316.3	320.3	4.0	
Goodwill	85.5	87.6	2.1	
Intangible assets	171.4	186.7	15.3	
Investments accounted for using the equity method	2.6	2.3	-0.3	
Other financial assets	141.6	149.3	7.8	
Deferred tax assets	122.6	135.2	12.6	
Other non-current assets	23.5	25.0	1.5	
Total non-current assets	863.4	906.5	43.0	
Total assets	1,854.0	1,838.1	-16.0	

(Billions of yen)

	Mar 2014	Sep 2014	YoY	Notes
Liabilities and equity				
Current liabilities				
Trade and other payables	245.4	229.5	-15.9	
Bonds and borrowings	160.3	102.9	-57.4	Redemption of bonds: Daiichi Sankyo -60.0 Bn
Other financial liabilities	15.1	12.7	-2.4	
Income taxes payable	5.6	12.0	6.4	
Provisions	22.7	24.4	1.7	
Other current liabilities	12.0	15.6	3.7	
Total current liabilities	461.2	397.2	-64.0	
Non-current liabilities				
Bonds and borrowings	263.3	256.1	-7.2	
Other financial liabilities	14.2	9.2	-4.9	
Post employment benefit liabilities	8.9	8.9	-0.0	
Provisions	3.7	3.8	0.1	
Deferred tax liabilities	39.8	44.7	4.9	
Other non-current liabilities	55.3	56.5	1.2	
Total non-current liabilities	385.3	379.3	-6.1	
Total liabilities	846.5	776.4	-70.1	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	0.0	
Capital surplus	105.3	105.3	0.0	
Treasury shares	-14.4	-14.3	0.1	
Other components of equity	121.8	145.4	23.7	Exchange differences on translation of foreign operations +17.1 Bn, Financial assets measured at fair value through other comprehensive income +6.4 Bn
Retained earnings	717.3	746.4	29.1	Profit for the year(owners of the Company) +50.3 Bn, Dividends -21.1 Bn
Total equity attributable to owners of the Company	979.9	1,032.7	52.8	
Non-controlling interests				
Non-controlling interests	27.6	28.9	1.3	
Total equity	1,007.5	1,061.6	54.1	
Total liabilities and equity	1,854.0	1,838.1	-16.0	

10. Consolidated Statement of Cash Flows

(Billions of yen)

	FY2013 Q2 Results	FY2014 Q2 Results	YoY	Notes
Cash flows from operating activities				
Profit before tax	43.9	65.4	21.5	
Depreciation and amortization	24.3	25.6	1.3	
(Increase) decrease in receivables and payables	-11.0	-13.6	-2.7	
Other, net	-58.3	-13.0	45.3	FY2013: Ranbaxy payment for settlement expenses (-49.8 Bn)
Income taxes paid	-23.8	-7.5	16.2	
Net cash flows from operating activities	-24.9	56.8	81.6	
Cash flows from investing activities				
Net (increase) decrease in time deposits and securities	-66.6	67.2	133.9	
(Acquisition of) proceeds from sales of fixed assets	-23.3	-41.3	-18.0	
Other, net	1.8	-0.1	-1.9	
Net cash flows from investing activities	-88.1	25.8	113.9	
Cash flows from financing activities				
Proceeds from bonds and borrowings	159.1	25.7	-133.4	
Repayments of bonds and borrowings	-27.8	-96.0	-68.2	
Dividends paid	-21.1	-21.1	-0.0	
Other, net	-0.5	-0.5	-0.0	
Net cash flows from financing activities	109.7	-92.0	-201.6	
Net increase (decrease) in cash and cash equivalents	-3.3	-9.4	-6.1	
Cash and cash equivalents at the beginning of the period	191.1	183.1	-8.1	
Effect of exchange rate changes on cash and cash equivalents	7.7	6.6	-1.1	
Cash and cash equivalents at the end of the period	195.5	180.3	-15.2	

11. Accounting Treatment when Ranbaxy Group is Unconsolidated (Planned)

Accounting Treatment in Consolidated Statement of Profit or Loss

	Currently	RLL When unconsolidated
[Continuing operation] Revenue	DS+RLL	DS* ¹
Operating profit	DS+RLL	DS* ¹
Profit before tax	DS+RLL	DS* ¹
Profit for the year	DS+RLL	DS* ¹
[Discontinued operation] Profit for the year	-	RLL* ² Gain on valuation* ³
Profit for the year	-	DS+RLL

*DS: Daiichi Sankyo Group RLL: Ranbaxy Group

1. The Ranbaxy Group's operating results will be excluded from the continuing operation.
2. The Ranbaxy Group's operating results will be recorded as profit for the year from the discontinued operation.
3. Gain on valuation from the exchange of Ranbaxy and Sun Pharma shares (the difference between the market value of Sun Pharma shares and the portion of the pre-merger equity of Ranbaxy Group that is the Company's interest outside the non-controlling interest) will be included in profit for the year from the discontinued operation.

Accounting Treatment in Consolidated Statement of Financial Position

	Currently	RLL When unconsolidated
Current assets	DS+RLL	DS* ¹
Non-current assets	DS+RLL	DS* ¹ Sun Pharma shares* ²

	Currently	RLL When unconsolidated
Current liabilities	DS+RLL	DS* ¹
Non-current liabilities	DS+RLL	DS* ¹ Deferred tax liabilities, etc.* ⁴
Equity	DS+RLL* ³	DS+RLL* ³ Retained earnings, etc.* ⁴

1. The Ranbaxy Group's assets and liabilities will be excluded.
2. Sun Pharma shares in the exchange with Ranbaxy shares will be recorded at their market value as investment securities under non-current assets.
3. Of the equity of Ranbaxy Group, the non-controlling interest outside the Company's interest will be excluded. The Company's interest will not be excluded.
4. The difference between the market value of Sun Pharma shares and the pre-merger equity of Ranbaxy Group (the Company's interest outside the non-controlling interest) will be recorded in equity (retained earnings, etc.) and liabilities (deferred tax liabilities, etc.).

12. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	
Japan Company (domestic sales)						
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo		
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca	
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	analgesic and anti-inflammatory	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Memary			2011	Merz		
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo		
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo		
Artist	carvedilol	antihypertensive	1993	Roche		
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo		
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Pralia	denosumab	anti-RANKL antibody	2013	Amgen		
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca	
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	
Lixiana	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2011	Daiichi Sankyo		
Effient	prasugrel	antiplatelet	2014	Daiichi Sankyo Ube Industries		
Daiichi Sankyo, Inc. (US)						
Olmesartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo		
Azor	olmesartan / amlodipine		2007			
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly	
Luitpold Pharmaceuticals, Inc. (US)						
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius	
Injectafer	ferric carboxymaltose injection	iron deficiency anemia	2013	Vifor Pharma		
Daiichi Sankyo Europe GmbH						
Olmesartan						
Olmetec	olmesartan		2002		Menarini Pfizer Nycomed	
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo		
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly	

MEMO

(This page is intentionally left blank)

13. Major R&D Pipeline (Innovative pharmaceuticals)

As of October 2014

◆ Launched/Approved

Generic Name	Class	Indication	Region	Status	Remarks
Edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	JP	<u>Approved</u>	<u>Sep 2014</u>
		Venous thromboembolism (VTE)	JP	<u>Approved</u>	
The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.					

Underline: change after FY2014 1Q Financial Announcement in July 2014

◆ Filed

Generic Name	Class	Target indication	Region	Filing year/month
Edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	US/EU	Jan 2014
			Others	CH (14/2*), BR (14/6) TW (14/7), <u>KR (14/9)</u> * means February, 2014, ditto
		Venous thromboembolism (VTE)	US/EU	Jan 2014
			Others	CH (14/2), BR (14/6) TW (14/7), <u>KR (14/9)</u>
			The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.	

Underline: change after FY2014 1Q Financial Announcement in July 2014

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		Remarks
Prasugrel	Anti-platelet agent	Ischemic stroke	JP	P3	additional indication
		Sickle cell disease	US	P3	additional indication
Denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	additional indication
		Rheumatoid arthritis	JP	P3	additional indication
Levofloxacin	New quinolone	Infection disease	JP	P3	Injection, additional indication
Tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
Nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
		Esophageal cancer	JP	P1	
Vemurafenib	BRAF inhibitor	Melanoma adjuvant*	US/EU	P3	additional indication (newly included in align with the description of Roche)
		Colorectal cancer	US/EU	P2	additional indication
Mirogabalin	$\alpha 2\delta$ ligand	<u>Fibromyalgia</u>	<u>US/EU</u>	<u>P3</u>	
		Chronic pain	JP	P2	P3 to be started in FY2014
Hydromorphone	opioid mu-receptor agonist	Cancer pain	JP	P3	
<u>CHS-0214</u>	<u>TNFα inhibitor</u>	<u>Rheumatoid Arthritis</u>	<u>JP</u>	<u>P3</u>	<u>etanercept biosimilar</u>
<u>CL-108</u>	<u>opioid mu-receptor agonist combination</u>	<u>Acute pain</u>	<u>US</u>	<u>P3</u>	<u>co-develop with Charleston Laboratories</u>
CS-3150	MR antagonist	Hypertension	JP	P2	
		Diabetic nephropathy	JP	P2	
DS-8500	GPR119 agonist	Diabetes	JP	P2	
Patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
		Non small cell lung cancer	JP	P1	
		Breast cancer	US	P2	
		Breast cancer	JP	P1	
PLX3397	Fms/Kit/Flt3-ITD inhibitor	Acute myeloid leukemia	US	P2	
		Glioblastoma	US	P2	
		Melanoma	US	P2	
		Pigmented villonodular synovitis	US	P1	
SUN13837	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2	
GE-145	X-ray contrast media	Angiography	JP	P2	
Laninamivir	Neuraminidase inhibitor	Influenza	US/EU	P2	out-licenseing with Biota
DS-1040	TAF1a inhibitor	Acute ischemic stroke	-	P1	
U3-1565	Anti-HB-EGF antibody	Solid cancer	US/JP	P1	
DS-7423	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1	

Underline: change after FY2014 1QFinancial Announcement in July 2014

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		Remarks
DS-3078	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1	
DS-3032	MDM2 inhibitor	Solid cancer, lymphoma	US	P1	
PLX7486	Fms/Trk inhibitor	Solid cancer	US	P1	
DS-8895	Anti-EPHA2 antibody	Solid cancer	JP	P1	
DS-8273	Anti-DR5 antibody	Solid cancer	US	P1	
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US	P1	
DS-6051	<u>NTRK/ROS1 inhibitor</u>	<u>Solid cancer</u>	<u>US</u>	<u>P1</u>	
PLX5622	FMS kinase inhibitor	Rheumatoid arthritis	-	P1	
DS-1093	HIF-PH inhibitor	Anemia of chronic kidney disease	-	P1	
DS-3801	GPR 38 agonist	Chronic obstipation	-	P1	
DS-1971	Pain	Chronic pain	-	P1	

Underline: change after FY2014 1QFinancial Announcement in July 2014

◆ Stage-up (major changes from the FY2014 1Q financial announcement in July 2014)

Generic Name / Project code number	Class	Target indication	Current stage	
Edoxaban	FXa inhibitor	Atrial Fibrillation (AF)	JP	Approval
			Others	Filed (KR)
		Venous thromboembolism (VTE)	JP	Approved
			Others	Filed (KR)
Mirogabalin / DS-5565	$\alpha 2\delta$ ligand	Fibromyalgia	US/EU	P3
CHS-0214	TNF α inhibitor	Rheumatoid Arthritis	JP	P3
CL-108	opioid mu-receptor agonist	Acute Pain	US	P3
DS-6051	NTRK/ROS1 inhibitor	Solid Cancer	US	P1

◆ Discontinue (major changes from the FY2014 1Q financial announcement in July 2014)

Generic Name / Project code number	Class	Target indication	Stage	
DS-7309	Glucokinase activator	Diabetes	-	P1
< Reason for discontinuation>				
Daiichi Sankyo decided not to develop this compound by ourselves in order to concentrate management resources on promising business areas.				

◆ Major R&D Pipeline Table

As of October, 2014

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<div><div>DS-7309 (US) (Diabetes / Glucokinase activator)</div><div>DS-1040 (Acute ischemic stroke / TAFIa inhibitor)</div></div>	<div><div>CS-3150 (JP) (Hypertension / Diabetic nephropathy / MR antagonist)</div><div>DS-8500 (JP) (Diabetes / GPR119 agonist)</div></div>	<div><div>Prasugrel (JP) (CS-747 / ischemic stroke / anti-platelet agent)</div><div>Prasugrel (US) (CS-747 / sickle cell disease / anti-platelet agent)</div></div>	<div><div>Edoxaban (JP) (DU-176b / AF / oral factor Xa inhibitor)</div><div>Edoxaban (US/EU/Others) (DU-176b / AF / oral factor Xa inhibitor)</div><div>Edoxaban (JP) (DU-176b / VTE / oral factor Xa inhibitor)</div><div>Edoxaban (US/EU/Others) (DU-176b / VTE / oral factor Xa inhibitor)</div></div>
Oncology	<div><div>U3-1565 (US/JP) (Anti-HB-EGF antibody)</div><div>DS-7423 (US/JP) (PI3K/mTOR inhibitor)</div><div>DS-3078 (US/EU) (mTOR inhibitor)</div><div>DS-3032 (US) (MDM2 inhibitor)</div><div>PLX7486 (US) (Fms/Trk inhibitor)</div><div>DS-8895 (JP) (Anti-EPHA2 antibody)</div><div>DS-8273 (US) (Anti-DR5 antibody)</div><div>PLX8394 (US) (BRAF inhibitor)</div><div>DS-6051 (US) (NTRK/ROS1 inhibitor)</div></div>	<div><div>Patritumab (US/EU) (U3-1287 / anti-HER3 antibody)</div><div>Vemurafenib (US/EU) (PLX4032 / BRAF inhibitor)</div><div>PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor)</div></div>	<div><div>Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor)</div><div>Denosumab (JP) (AMG 162 / breast cancer adjuvant / anti-RANKL antibody)</div><div>Nimotuzumab (JP) (DE-766 / Gastric cancer / anti-EGFR antibody)</div><div>Vemurafenib (US/EU)* (PLX4032 / melanoma adjuvant / BRAF inhibitor) *: added to align with Roche's description</div></div>	
Others	<div><div>PLX5622 (Rheumatoid arthritis / FMS kinase inhibitor)</div><div>DS-1093 (Anemia of chronic kidney disease/HIF-PH inhibitor)</div><div>DS-3801 (Chronic obstipation/GPR 38 agonist)</div><div>DS-1971 (Chronic pain)</div></div>	<div><div></div><div>Mirogabalin (JP) (DS-5565 / Chronic pain / $\alpha 2\delta$ ligand)</div><div>SUN13837 (US/EU) (Spinal cord injury / Modulator of bFGF signaling system)</div><div>Laninamivir (US/EU) (CS-8958 / anti-influenza / Out licensing with Biota)</div><div>Ioforminol (JP) (GE-145 / X-ray contrast media/Angiography)</div></div>	<div><div>Mirogabalin (US/EU) (DS-5565 /Fibromyalgia / $\alpha 2\delta$ ligand)</div><div>Levofloxacin (JP) (DR-3355 / anti-infection / New quinolone)</div><div>Denosumab (JP) (AMG 162 / Rheumatoid arthritis / anti-RANKL antibody)</div><div>Hydromorphone (JP) (DS-7113 / Cancer pain/ opioid mu-receptor agonist)</div><div>CHS-0214 (JP) (Rheumatoid arthritis / TNFa inhibitor)</div><div>CL-108 (US) (Acute pain / opioid mu-receptor agonist)</div></div>	

Cardiovascular-Metabolics

[Project after Phase 2]

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Edoxaban	DU-176b	Oral	Factor Xa inhibitor	- Atrial fibrillation (AF) - Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana (JP) LIXIANA (EU, Planned) SAVAYSA (US, Planned)
<p><Summary></p> <p>The once daily oral anti coagulant (FXa inhibitor). Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.</p> <ul style="list-style-type: none"> • [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana • Hokusai-VTE (VTE) P3 study was presented at ESC 2013. • ENGAGE AF-TIMI 48 (AF) P3 study was presented at AHA 2013. • NDA for AF/VTE indication Approved (JP: Sep 2014), Filed. (US/EU: Jan, 2014) 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Prasugrel	CS-747	Oral	Anti-platelet agent	- Ischemic stroke - Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efient (JPN, EU)
<p><Summary></p> <p>The oral antiplatelet agent. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery</p> <ul style="list-style-type: none"> • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan. • [JP] Approved in Mar-2014 for the ischemic heart disease undergoing PCI and launched in May-2014. P3 studies for ischemic stroke are on-going. • [US] P3 study in pediatric sickle cell disease patients is on-going. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CS-3150	Oral	MR antagonist	- Hypertension - Diabetic nephropathy	Exelixis	TBD
<p><Summary></p> <p>The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.</p> <ul style="list-style-type: none"> • P2 study in essential hypertension in Japan was completed. • P2 study in diabetes with albuminuria in Japan was completed. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	DS-8500	Oral	GPR119 agonist	- Diabetes	Daiichi Sankyo	TBD
<p><Summary></p> <p>The agent agonistically acts on GPR119 which is expressed in small intestine and spleen cells, stimulates insulin secretion, and lowers blood sugar concentration.</p>						

Oncology

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Tivantinib	ARQ 197	Oral	Met inhibitor	- Hepatocellular cancer	ArQule	TBD
<Summary> The molecular-targeted agent to inhibit HGF(hepatocyte growth factor) receptor, Met which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction. • A P3 clinical study for HCC with MET high patients was started in Jan-2013.						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Nimotuzumab	DE-766	Injection	Anti-EGFR antibody	- Gastric cancer - Esophageal cancer	InnoMab	TBD
<Summary> The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies. • P3 in Japan for Gastric cancer started in April 2013.						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Patritumab	U3-1287	Injection	Anti-HER3 antibody	- Non small cell lung cancer - Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<Summary> The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Vemurafenib	PLX4032	Oral	BRAF inhibitor	- Melanoma adjuvant - Colorectal cancer	Daiichi Sankyo (Plexxikon)	Zelboraf
<Summary> The molecular-targeted agent to inhibit BRAF V600E mutation. Launched since 2011 as personalized treatment for patients with unresectable or metastatic melanoma.						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	PLX3397	Oral	Fms/Kit/Flt3-ITD inhibitor	- Acute myeloid leukemia - Glioblastoma - Melanoma - Pigmented villonodular synovitis	Daiichi Sankyo (Plexxikon)	TBD
<Summary> The molecular-targeted agent to inhibit Fms, Kit and Flt-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.						

Others

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Denosumab	AMG 162	Injection	Anti-RANKL antibody	- Breast cancer adjuvant - Rheumatoid arthritis	Amgen	SRE, GCTB: Ranmark(JP) Osteoporosis: Pralia(JP)
<p><Summary></p> <p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, in June 2013 as treatment for osteoporosis, and in May 2014 as treatment for giant cell tumor of bone.</p> <ul style="list-style-type: none"> • July, 2007 In-licensed from Amgen. • P3 : Breast cancer adjuvant, Rheumatoid arthritis. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Levofloxacin	DR-3355	Injection	New quinolone	- Infection disease	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<p><Summary></p> <ul style="list-style-type: none"> • Levofloxacin injection formation, which was launched in 2011 for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are completed. • A P3 comparative study for urinary tract infection and 4 open studies are completed. CTD creation is ongoing. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
	CHS-0214	Injection	TNF α inhibitor	- Rheumatoid arthritis	Coherus	TBD
<p><Summary></p> <p>Biosimilar product for etanercept</p> <ul style="list-style-type: none"> • Phase 3 study for patients with rheumatoid arthritis in Japan was started in August 2014. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
	CL-108	Oral	opioid mu-receptor regulator	- Acute pain	Charleston Laboratories	TBD
<p><Summary></p> <p>Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of Opioid-Induced Nausea and Vomiting is expected.</p> <ul style="list-style-type: none"> • Under phase 3 development in collaboration with Charleston Laboratories 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Mirogabalin	DS-5565	Oral	$\alpha 2\delta$ ligand	- Fibromyalgia - Chronic pain	Daiichi Sankyo	TBD
<p><Summary></p> <p>The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.</p> <ul style="list-style-type: none"> • Ph2 studies for diabetic peripheral neuropathic pain were completed. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Hydromorphone	DS-7113	Oral/ Injection	opioid mu-receptor regulator	- Cancer pain	-	TBD
<p><Summary></p> <p>The opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. It is designated as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need".</p>						

Generic Name	Project code Number	Dosage Form	Class	- Target Indication	Origin	Brand Name
-	SUN13837	Injection	Modulator of bFGF signaling system	- Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<p><Summary> By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
loforminol	GE-145	Injection	X-ray contrast media	- Angiography	GE Healthcare	TBD
<p><Summary> Dimeric X-ray contrast medium, which is expected to reduce heat sensation and pain.</p>						

1. Summary of Consolidated Statement of Profit or Loss (IFRS FY2013)

JPY Bn	Q1		Q2		Q3 ^{*3}		Q4 ^{*3}		FY2013			
	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	YoY	YoY
Revenue	100%	252.6	100%	264.1	100%	288.8	100%	312.7	100%	1,118.2	123.6	12.4%
Cost of sales	35%	87.6	33%	86.5	35%	102.4	40%	125.8	36%	402.3	63.8	18.8%
Gross Profit	65%	165.0	67%	177.7	65%	186.3	60%	186.9	64%	716.0	59.8	9.1%
SG&A expenses	40%	101.7	35%	93.4	32%	91.5	40%	126.5	37%	413.2	40.2	10.8%
(General expenses) ^{*1}	35%	88.1	34%	90.7	34%	98.6	38%	120.0	36%	397.3		
(Asset related expenses) ^{*2}	1%	2.9	1%	2.8	-3%	-8.7	2%	6.0	0%	3.0		
(Loss on restructuring)	4%	10.8	0%	-0.1	1%	1.5	0%	0.6	1%	12.9		
R&D expenses	19%	48.1	18%	46.7	15%	42.2	17%	54.1	17%	191.2	6.8	3.7%
Operating Profit	6%	15.2	14%	37.5	18%	52.6	2%	6.3	10%	111.6	12.8	13.0%
Financial income/expenses		2.5		-10.9		-2.8		0.9		16.6	-7.9	
Share of profit or loss of investments accounted for using the equity method		-0.1		-0.2		-0.0		-1.1		26.9	16.6	
Profit before tax	7%	17.5	10%	26.3	17%	49.8	2%	6.1	9%	99.8	3.9	4.1%
Income taxes		2.1		10.1		14.5		19.7		46.4	16.5	
Profit for the year	6%	15.4							5%	53.4	16.5	
Profit attributable to owners of the Company	6%	15.0	7%	18.5	13%	38.0	-3%	-10.5	5%	60.9	-3.1	-4.8%
Currency Rate	Q1		Q2 YTD		Q3 YTD		Q4 YTD		FY2013			
	Results		Results		Results		Results		Results	YoY		
USD/JPY (average)	98.76		98.86		99.39		100.24		100.24	+17.13		
EUR/JPY (average)	128.96		130.01		132.24		134.38		134.38	+27.23		
INR/JPY (average)	1.71		1.74		1.69		1.68		1.68	+0.18		

^{*1} Incl. A&P expenses, Personnel expenses and other SG&A expenses

^{*2} Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

^{*3} Under reviewing based on the law of Financial Instruments and Exchange Act at the timing of disclosure

2. Segment Information

Daiichi Sankyo Group	Q1		Q2		Q3		Q4		FY2013			
	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	YoY	YoY
External revenue		210.0		218.3		244.3		225.0		897.7		
Intersegment revenue		0.4		0.4		0.4		0.3		1.4		
Revenue	100%	210.4	100%	218.7	100%	244.7	100%	225.3	100%	899.1	86.2	11%
Cost of sales	31%	65.9	29%	63.4	32%	77.2	34%	76.5	31%	282.9	26.9	10%
Gross Profit	69%	144.5	71%	155.3	68%	167.5	66%	148.8	69%	616.2	59.3	11%
SG&A expenses	40%	84.1	35%	75.6	30%	73.2	40%	89.8	36%	322.7	24.6	8%
(General expenses) ^{*1}	34%	72.1	34%	74.4	33%	81.4	38%	86.7	35%	314.6		
(Asset related expenses) ^{*2}	1%	1.2	1%	1.2	-4%	-9.7	1%	2.5	-1%	-4.8		
(Loss on restructuring)	5%	10.8	0%	-0.1	1%	1.5	0%	0.6	1%	12.9		
R&D expenses	22%	45.8	20%	44.2	16%	40.3	22%	50.3	20%	180.7	3.5	2%
Operating Profit	7%	14.6	16%	35.5	22%	54.0	4%	8.7	13%	112.9	31.1	38%
Financial income and expense		1.4		-1.2		3.0		-2.7		0.6	-0.1	
Share of profit or loss of investments accounted for using the equity method		-0.1		-0.1		0.1		-0.5		-0.6	-0.7	
Profit before tax	8%	15.9	16%	34.3	23%	57.2	2%	5.6	13%	112.9	30.4	37%
Income taxes		2.3		13.5		15.7		15.6		47.1	26.2	
Profit for the year		13.6		20.7		41.5		-10.0		65.8	4.2	
Profit attributable to owners of the Company	7%	13.9	10%	21.3	17%	41.8	-4%	-8.2	8%	68.8	7.4	12%
Ranbaxy Group												
External revenue		42.6		45.8		44.4		87.7		220.6		
Intersegment revenue		0.3		0.3		0.5		1.0		2.1		
Revenue	100%	42.9	100%	46.1	100%	44.9	100%	88.7	100%	222.7	37.5	20%
Cost of sales	52%	22.3	52%	23.8	57%	25.8	57%	50.5	55%	122.4	37.5	44%
Gross Profit	48%	20.6	48%	22.3	43%	19.1	43%	38.2	45%	100.3	0.0	0%
SG&A expenses	39%	16.9	41%	19.1	39%	17.4	41%	36.3	40%	89.8	17.5	24%
R&D expenses	6%	2.6	6%	2.6	5%	2.1	5%	4.2	5%	11.5	3.5	43%
Operating Profit	3%	1.2	1%	0.6	-1%	-0.4	-3%	-2.3	0%	-1.0	-20.9	-105%
Financial income and expense		1.0		-9.9		-6.0		0.7		-14.2	-10.9	
Share of profit or loss of investments accounted for using the equity method		-0.0		-0.1		-0.1		-0.1		-0.2	0.0	
Profit before tax	5%	2.1	-20%	-9.4	-14%	-6.5	-2%	-1.7	-7%	-15.4	-31.8	-194%
Income taxes		-0.5		-3.2		-0.9		3.8		-0.8	-7.2	
Profit for the year		2.6		-6.2		-5.6		-5.4		-14.6	-24.6	
Profit attributable to owners of the Company	6%	2.6	-14%	-6.2	-12%	-5.6	-6%	-5.3	-7%	-14.6	-24.4	-248%
Inter-segment Transactions												
Revenue		-0.7		-0.8		-0.9		-1.3		-3.6	-0.1	
Cost of sales		-0.6		-0.7		-0.5		-1.1		-3.0	-0.5	
Gross Profit		-0.1		-0.0		-0.3		-0.1		-0.6	0.5	
SG&A expenses		0.8		-1.3		0.8		0.4		0.7	-2.0	
R&D expenses		-0.3		-0.1		-0.1		-0.4		-0.9	-0.2	
Operating Profit		-0.6		1.4		-1.0		-0.1		-0.4	2.6	
Financial income and expense		0.1		0.1		0.2		2.8		3.2	3.1	
Share of profit or loss of investments accounted for using the equity method		-0.0		-0.0		-0.0		-0.5		-0.6	-0.4	
Profit before tax		-0.6		1.5		-0.9		2.2		2.2	5.3	
Income taxes		0.3		-0.3		-0.3		0.4		0.1	-2.6	
Profit for the year		-0.9		1.7		-0.6		1.9		2.1	7.9	
Profit attributable to owners of the Company		-1.5		3.4		1.7		3.0		6.7	13.9	

*1 Incl. A&P expenses, Personnel expenses and other SG&A expenses

*2 Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

3. Revenue by Business Units (FY2013)

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013*			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																	
Consolidated Revenue	1,110.0	252.5	+4.1%	23%	263.9	+9.3%	24%	290.7	+11.2%	26%	311.2	+23.4%	28%	1,118.2	123.6	+12.4%	101%
Japan Company (domestic sales)+Vaccine business	485.0	108.5	+8.7%	-	117.1	+5.5%	-	138.6	+11.1%	-	122.3	+5.7%	-	486.5	30.5	+6.7%	-
Olmotec	83.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%	18.7	-5.9%	23%	79.1	0.8	+1.0%	95%
Rezaltas	21.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%	4.3	+1.0%	21%	18.5	1.5	+9.1%	88%
Calblock	9.0	2.4	-11.1%	27%	2.4	-14.5%	26%	2.3	-18.2%	26%	1.8	-30.2%	20%	8.9	-2.0	-18.3%	99%
Loxonin	61.0	14.9	+5.8%	25%	15.7	+0.6%	26%	16.2	-0.1%	27%	12.5	-9.1%	20%	59.3	-0.3	-0.6%	97%
Cravit	35.0	7.6	-5.4%	22%	8.1	-4.0%	23%	10.2	-4.4%	29%	7.6	-13.1%	22%	33.5	-2.4	-6.7%	96%
Nexium	52.0	10.9	+562.1%	21%	13.1	+375.9%	25%	16.2	+95.3%	31%	14.0	+58.1%	27%	54.2	32.7	+151.5%	104%
Memary	34.0	6.6	+28.7%	19%	7.8	+38.2%	23%	9.5	+43.9%	28%	9.5	+46.5%	28%	33.3	9.5	+40.0%	98%
Mevalotin	22.0	5.2	-20.5%	24%	5.9	-12.5%	27%	5.9	-10.0%	27%	4.5	-24.9%	20%	21.5	-4.3	-16.8%	98%
Artist	22.0	5.4	-3.4%	25%	5.7	+0.6%	26%	6.0	+3.6%	28%	5.3	-0.9%	24%	22.4	0.0	+0.0%	102%
Omnipaque	19.0	4.7	-4.0%	25%	5.2	-0.7%	28%	5.6	+4.3%	29%	4.1	-10.7%	22%	19.7	-0.5	-2.5%	104%
Urief	12.0	2.7	+0.1%	22%	2.9	+4.2%	24%	3.2	+9.4%	27%	2.6	-2.1%	22%	11.4	0.3	+3.1%	95%
Inavir	10.0	0.3	-38.8%	3%	0.0	-90.6%	0%	1.8	-15.2%	18%	11.4	+33.3%	114%	13.4	2.3	+20.8%	135%
Ranmark	7.0	1.6	+162.8%	22%	1.9	+68.0%	27%	2.4	+76.8%	34%	2.3	+64.2%	32%	8.1	3.6	+82.2%	115%
Pralia	not disclosed	0.4	-	-	0.6	-	-	0.8	-	-	1.5	-	-	3.2	3.2	-	-
Daiichi Sankyo Espha products	not disclosed	2.9	+3.6%	-	3.0	+13.2%	-	3.8	+27.3%	-	2.7	+4.5%	-	12.5	1.4	+12.5%	-
Vaccines business	not disclosed	9.3	+64.2%	-	8.3	-26.3%	-	13.9	-8.6%	-	6.1	-13.8%	-	37.5	-1.6	-4.2%	-
Daiichi Sankyo Healthcare (OTC)	48.0	9.8	-4.6%	20%	13.1	+2.5%	27%	14.1	-2.8%	29%	11.0	+16.1%	23%	48.1	1.0	+2.1%	100%
Daiichi Sankyo, Inc. (US)	163.0	46.6	+29.7%	29%	39.9	+22.2%	25%	44.6	+19.3%	27%	40.7	+11.9%	25%	171.8	29.4	+20.7%	105%
Olmesartan	103.0	30.7	+28.4%	30%	26.1	+20.0%	25%	28.7	+11.8%	28%	26.8	+13.6%	26%	112.3	17.4	+18.3%	109%
Benicar/Benicar HCT	79.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%	20.3	+16.3%	26%	85.9	12.6	+17.2%	109%
Azor	15.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%	4.6	+13.6%	31%	17.4	2.6	+17.4%	116%
Tribenzor	8.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%	1.9	-8.5%	24%	9.0	2.2	+32.3%	113%
Welchol	43.0	11.4	+37.4%	26%	9.6	+33.8%	22%	11.7	+39.8%	27%	9.6	+3.2%	22%	42.3	9.1	+27.6%	98%
Effient (alliance revenue)	not disclosed	4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-	4.0	+32.6%	-	15.4	4.9	+46.7%	-
Luitpold Pharmaceuticals, Inc. (US)	40.0	8.1	-28.7%	20%	10.2	+32.0%	25%	9.6	-15.6%	24%	11.8	+43.6%	30%	39.6	1.0	+2.6%	99%
Venofer	26.0	4.9	-27.7%	19%	6.8	+76.5%	26%	6.4	-23.0%	25%	6.8	+45.7%	26%	24.9	1.3	+5.4%	96%
Injectafer	not disclosed	-	-	-	0.2	-	-	0.3	-	-	0.8	-	-	1.3	1.3	-	-
Daiichi Sankyo Europe GmbH	78.0	19.0	+36.8%	24%	21.4	+41.8%	27%	23.3	+37.6%	30%	20.2	+9.3%	26%	83.9	19.5	+30.3%	108%
Olmesartan	60.0	14.4	+45.0%	24%	16.8	+48.0%	28%	18.7	+44.7%	31%	15.8	+14.0%	26%	65.6	17.6	+36.7%	109%
Olmotec/Olmotec Plus	41.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%	10.5	+10.7%	26%	44.5	11.9	+36.7%	109%
Sevikar	12.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%	3.4	+19.5%	29%	13.5	2.7	+25.3%	112%
Sevikar HCT	6.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%	1.9	+23.6%	32%	7.6	2.9	+62.9%	127%
Efient (alliance revenue)	not disclosed	1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-	1.2	+1.2%	-	4.7	-	+20.5%	-
Asia, South and Central America (ASCA)	46.0	12.7	+49.0%	-	14.1	+50.8%	-	15.0	+55.8%	-	16.9	-9.5%	-	58.8	12.6	+27.3%	-
Daiichi Sankyo China	not disclosed	4.7	+77.3%	-	4.9	+62.6%	-	5.3	+71.4%	-	6.3	-18.1%	-	21.2	4.8	+29.2%	-
Daiichi Sankyo Taiwan	not disclosed	1.1	+40.0%	-	1.1	+37.5%	-	1.1	+37.6%	-	1.2	+28.4%	-	4.5	1.2	+35.6%	-
Daiichi Sankyo Korea	not disclosed	1.8	+44.6%	-	2.2	+79.1%	-	2.7	+102.1%	-	2.4	+55.3%	-	9.1	3.7	+69.8%	-
Daiichi Sankyo (Thailand)	not disclosed	0.4	+46.7%	-	0.4	+36.5%	-	0.8	+107.1%	-	0.9	+112.9%	-	2.5	1.1	+81.4%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.7	+40.8%	-	2.0	+72.5%	-	2.0	+100.5%	-	1.8	-44.5%	-	7.5	0.9	+13.8%	-
Daiichi Sankyo Venezuela	not disclosed	1.3	+48.4%	-	1.8	+22.7%	-	1.5	-1.5%	-	2.4	-18.4%	-	6.9	0.2	+2.7%	-
Ranbaxy Group**	224.0	42.3	-28.4%	-	45.7	-4.1%	-	44.5	+16.0%	-	88.1	+118.4%	-	220.6	35.1	+19.0%	-
Others	26.0	5.5	-20.3%	-	2.4	-77.7%	-	1.1	-89.2%	-	0.1	-100.6%	-	9.0	-5.5	-73.4%	-

* Of revenues included in "Others", revenues of "Export, royalty to US/EU region" is transferred to Japan Company, revenues of "Licensee business in ASCA region" is transferred to ASCA Company, revenues of "Vaccine business" is transferred to "Vaccine business" under Japan Company, respectively.

** Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

[Reference] Revenue in Local Currency

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																	
Daiichi Sankyo, Inc. (US)	1,682	472	+5.3%	28%	403.0	-3.0%	24%	444.0	-3.6%	26%	395.0	+1.7%	24%	1,714	1	+0.1%	102%
Olmesartan	1,063	311	+4.3%	29%	263	-4.7%	25%	286	-9.7%	27%	260	+3.8%	25%	1,120	-22	-1.9%	105%
Benicar/Benicar HCT	815	241	+2.4%	30%	204	-4.3%	25%	215	-13.7%	26%	197	+7.1%	24%	857	-25	-2.8%	105%
Azor	155	47	+6.9%	30%	38	-13.2%	25%	44	-6.6%	28%	45	+2.5%	29%	174	-5	-2.7%	112%
Tribenzor	83	23	+21.3%	28%	21	+10.5%	26%	26	+31.6%	32%	19	-19.6%	23%	90	8	+9.7%	109%
Welchol	444	115	+11.6%	26%	97	+6.2%	22%	116	+13.0%	26%	93	-7.8%	21%	422	23	+5.8%	95%
Effient (alliance revenue)	not disclosed	41	+34.0%	-	37	+23.2%	-	38	+12.0%	-	39	+18.7%	-	154	27	+21.6%	-
USD Mn																	
Luitpold Pharmaceuticals, Inc. (US)	413	82	-42.1%	20%	103.0	+4.4%	25%	95.0	-31.9%	23%	115.0	+36.2%	28%	395	-69	-14.9%	96%
Venofer	268	50	-41.2%	19%	68	+39.2%	26%	64	-38.0%	24%	66	+40.2%	25%	248	-36	-12.6%	93%
Injectafer	not disclosed	0	-	-	2	-	-	3	-	-	7	-	-	13	-	-	-
EUR Mn																	
Daiichi Sankyo Europe GmbH	600	147	+9.2%	25%	163.0	+6.8%	27%	171.0	+6.0%	29%	143.0	-6.0%	24%	624	23	+3.9%	104%
Olmesartan	462	111	+15.7%	24%	128	+11.6%	28%	137	+11.4%	30%	112	-2.0%	24%	488	40	+9.0%	106%
Olmetec/Olmetec Plus	315	76	+21.6%	24%	89	+7.7%	28%	93	+13.9%	30%	74	-5.1%	23%	331	27	+9.0%	105%
Sevikar	92	23	-4.6%	25%	23	-0.5%	25%	29	+0.4%	32%	24	+4.7%	27%	100	-0	-0.1%	109%
Sevikar HCT	46	12	+29.4%	27%	16	+77.5%	35%	15	+21.6%	32%	13	+4.1%	29%	57	13	+29.9%	123%
Efient (alliance revenue)	not disclosed	9	+4.0%	-	8	-7.5%	-	9	+2.2%	-	8	-13.2%	-	35	-1	-3.9%	-
INR Bn																	
Ranbaxy Group*	135	25	-33.5%	-	26.0	-19.7%	-	28.0	+1.5%	-	53.0	+96.7%	-	131	30	+6.2%	-

* Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

4. Revenue of Global Products (FY2013)

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																	
Olmesartan	289.0	71.4	+19.0%	25%	74.6	+22.7%	26%	81.9	+19.8%	28%	72.3	+3.7%	25%	300.2	41.3	+16.0%	104%
Olmetec (JPN)	83.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%	18.7	-5.9%	23%	79.1	0.8	+1.0%	95%
Rezaltas (JPN)	21.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%	4.3	+1.0%	21%	18.5	1.5	+9.1%	88%
Benicar/Benicar HCT (US)	79.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%	20.3	+16.3%	26%	85.9	12.6	+17.2%	109%
Azor (US)	15.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%	4.6	+13.6%	31%	17.4	2.6	+17.4%	116%
Tribenzor (US)	8.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%	1.9	-8.5%	24%	9.0	2.2	+32.3%	113%
Olmetec/Olmetec Plus (EU)	41.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%	10.5	+10.7%	26%	44.5	11.9	+36.7%	109%
Sevikar (EU)	12.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%	3.4	+19.5%	29%	13.5	2.7	+25.3%	112%
Sevikar HCT (EU)	6.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%	1.9	+23.6%	32%	7.6	2.9	+62.9%	127%
Other subsidiaries, export, etc	24.0	5.4	+35.4%	23%	6.2	+44.0%	26%	6.5	+49.9%	27%	6.7	-18.0%	28%	24.7	4.0	+19.2%	103%
Prasugrel	not disclosed	5.2	+55.6%	-	4.7	+46.3%	-	5.0	+37.2%	-	5.2	+24.0%	-	20.1	5.7	+39.6%	-
Effient alliance revenue (US)	not disclosed	4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-	4.0	+32.6%	-	15.4	4.9	+46.7%	-
Efient alliance revenue (EU)	not disclosed	1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-	1.2	+1.2%	-	4.7	0.8	+20.5%	-

1. Summary of Consolidated Income Statement (FY2012)

JPY Bn	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	242.6	+4.7%	100%	241.6	+7.7%	100%	261.5	+8.8%	100%	252.2	+4.1%	100%	997.9	59.2	+6.3%
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%
Operating Income	13%	32.5	-25.2%	10%	24.6	+31.2%	14%	36.5	+22.9%	3%	7.0	+10.2%	10%	100.5	2.3	+2.4%
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6	
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0	
Ordinary Income	17%	40.8	-9.0%	4%	9.0	-58.0%	18%	45.8	+128.3%	1%	3.5	-	10%	99.1	22.9	+30.1%
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7	
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9	
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9	
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8	
Net Income	8%	20.4	-19.4%	2%	4.0	-66.3%	10%	27.1	-	6%	15.1	-	7%	66.6	56.2	+541.6%
Effective tax rate		41%			78%			25%			-90%			26%		
Overseas sales ratio results		54%			48%			44%			49%			49%		

2. Currency Rate (FY2012)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012
	Results	Results	Results	Results	Results
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50
					YoY
					+4.04
					-1.81
					-0.23

3. Segment Information (FY2012)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
Net sales	100%	183.8	-4.2%	100%	194.2	+4.4%	100%	223.8	+9.2%	100%	212.4	+17.6%	100%	814.2	50.6	+6.6%
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
Operating Income	11%	20.1	-49.3%	10%	20.3	+8.9%	16%	34.7	+15.1%	4%	8.9	-	10%	84.0	0.3	+0.4%
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
Ordinary Income	11%	21.1	-49.2%	10%	19.8	+4.2%	16%	36.1	+16.1%	4%	8.8	-	11%	85.7	-1.3	-1.4%
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
Net Income	7%	13.7	-40.1%	5%	10.2	-4.6%	10%	23.2	+110.3%	9%	19.9	-	8%	67.0	29.7	+79.4%

Ranbaxy Group																
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6	
Net sales	100%	59.8	+49.5%	100%	47.9	+24.1%	100%	38.6	+7.5%	100%	40.8	-34.3%	100%	187.1	10.5	+6.0%
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%
Operating Income	23%	13.8	+161.9%	12%	5.6	+238.2%	7%	2.9	+238.4%	-1%	-0.5	-103.9%	12%	21.8	1.4	+7.0%
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3	
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9	
Ordinary Income	36%	21.2	+269.3%	-19%	-9.2	-317.5%	29%	11.0	-	-10%	-3.9	-	10%	19.1	22.6	-
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9	
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0	
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0	
Net Income	25%	15.0	+118.9%	-14%	-6.9	-297.1%	19%	7.4	-	-15%	-6.1	-	5%	9.4	43.1	-

Inter-segment Transactions																
Net sales		-1.0			-0.6			-1.0			-0.9			-3.5		
Cost of sales		-0.7			-0.4			-0.9			-0.7			-2.7		
Gross Profit		-0.3			-0.2			-0.0			-0.2			-0.7		
SG&A expenses		1.1			1.2			1.1			1.2			4.6		
R&D expenses		-0.3			-0.1			-0.1			-0.1			-0.6		
Other expenses		1.4			1.3			1.3			1.3			5.2		
Operating Income		-1.4			-1.4			-1.1			-1.4			-5.3		
Non-operating income		-0.0			-0.1			-0.1			0.0			-0.2		
Non-operating expenses		0.1			0.0			0.0			0.0			0.2		
Ordinary Income		-1.5			-1.5			-1.2			-1.4			-5.7		
Extraordinary income		-			0.0			0.0			0.1			0.1		
Extraordinary losses		0.0			-0.0			0.0			0.0			0.0		
Income before income taxes and minority interests		-1.5			-1.5			-1.2			-1.4			-5.6		
Income taxes		2.6			0.9			-0.3			-0.3			3.0		
Minority interests		4.2			-3.1			2.6			-2.4			1.3		
Net Income		-8.3			0.7			-3.5			1.3			-9.8		

4. Sales by Business Units (FY2012)

	FY2012 Plan	Results	Q1 YoY	to plan	Results	Q2 YoY	to plan	Results	Q3 YoY	to plan	Results	Q4 YoY	to plan	Results	FY2012 YoY	to plan
JPY Bn																
Consolidated Net Sales	990.0	242.6	+4.7%	25%	241.6	+7.7%	24%	261.5	+8.8%	26%	252.2	+4.1%	26%	997.9	+6.3%	101%
Japan Company (domestic sales)	440.0	98.2	-2.2%	22%	106.9	+6.3%	24%	124.7	+9.5%	28%	112.7	+18.8%	26%	442.5	+8.0%	101%
Olmetec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%
Memary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-
Daiichi Sankyo Healthcare (OTC)	48.0	10.2	+5.0%	21%	12.8	+1.1%	27%	14.5	+6.1%	30%	9.5	-2.4%	20%	47.1	+2.7%	98%
Daiichi Sankyo, Inc. (US)	139.0	35.9	+3.7%	26%	32.6	+10.0%	24%	37.4	+23.9%	27%	36.4	+11.6%	26%	142.3	+12.0%	102%
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Luitpold Pharmaceuticals, Inc. (US)	38.0	11.3	-10.9%	30%	7.7	-17.4%	20%	11.3	-24.7%	30%	8.2	+7.7%	22%	38.6	-13.7%	102%
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%
Daiichi Sankyo Europe GmbH	65.0	13.9	-17.6%	21%	15.1	-10.8%	23%	16.9	-2.6%	26%	18.5	-3.0%	29%	64.4	-8.3%	99%
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%
Olmetec/Olmetec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-
Asia, South and Central America (ASCA) ^{*1}	38.0	7.1	+9.8%	19%	8.1	+10.1%	21%	8.2	+18.4%	22%	17.1	+117.8%	45%	40.5	+41.6%	107%
Daiichi Sankyo China ^{*2}	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-
Ranbaxy Laboratories Limited	179.0	59.1	+48.7%	33%	47.6	+24.0%	27%	38.3	+7.5%	21%	40.3	-34.6%	23%	185.4	+5.7%	104%
Others	43.0	6.8	-38.0%	16%	10.7	+13.1%	25%	10.0	+32.8%	23%	9.5	+7.5%	22%	37.1	+0.5%	86%
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-

[Reference] Sales in Local Currency

		FY2012	Q1			Q2			Q3			Q4			FY2012		
		Plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn																	
Daiichi Sankyo, Inc. (US)		1,711	448	+5.7%	26%	415	+8.7%	24%	461.0	+18.2%	27%	389.0	-5.6%	23%	1,713	+6.5%	100%
Olmesartan		1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%
Benicar/Benicar HCT		898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%
Azor		172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%
Tribenzor		75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%
Welchol		388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%
Effient (alliance revenue)		not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-
USD Mn																	
Luitpold Pharmaceuticals, Inc. (US)		468	141	-9.2%	30%	98	-18.5%	21%	140.0	-27.6%	30%	85.0	-11.8%	18%	465	-17.9%	99%
Venofer		288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%
EUR Mn																	
Daiichi Sankyo Europe GmbH		650	135	-6.0%	21%	153	-0.2%	24%	161.0	-2.6%	25%	152.0	-16.6%	23%	601	-6.7%	93%
Olmesartan		480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%
Olmetec/Olmetec Plus		340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%
Sevikar		100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%
Sevikar HCT		40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%
Efient (alliance revenue)		not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-
INR Bn																	
Ranbaxy Laboratories Limited		105	37	+71.1%	35%	32	+53.1%	31%	27.0	+31.2%	26%	27.0	-28.9%	26%	124	+21.9%	117%

5. Sales of Global Products (FY2012)

		FY2012	Q1			Q2			Q3			Q4			FY2012		
		Plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																	
Olmesartan		251.0	60.0	-5.3%	24%	60.8	+0.6%	24%	68.3	+6.4%	27%	69.7	+13.0%	28%	258.9	+3.7%	103%
Olmetec (JPN)		76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas (JPN)		16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Benicar/Benicar HCT (US)		73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor (US)		14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor (US)		6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Olmetec/Olmetec Plus (EU)		34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar (EU)		10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT (EU)		4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Other subsidiaries, export, etc		18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%
Prasugrel		not disclosed	3.3	+52.6%	-	3.2	+37.5%	-	3.7	+43.5%	-	4.2	+10.4%	-	14.4	+32.5%	-
Effient alliance revenue (US)		not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Efient alliance revenue (EU)		not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07 -6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96 -4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73 -0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%
Ranbaxy Group																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-
Inter-segment Transactions																
Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmetec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmetec/Olmetec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexxikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Efient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-